Welcome to our dedicated page for Tonix Pharmaceut news (Ticker: TNXP), a resource for investors and traders seeking the latest updates and insights on Tonix Pharmaceut stock.
Tonix Pharmaceuticals Holding Corp. develops and commercializes biotechnology products for central nervous system disorders, immunology, infectious diseases and rare diseases. Company news centers on TONMYA, an FDA-approved cyclobenzaprine HCl sublingual tablet for fibromyalgia in adults, along with marketed acute migraine products Zembrace SymTouch and Tosymra.
Recurring updates also cover Tonix’s development pipeline, including TNX-4800, a long-acting anti-Borrelia OspA human monoclonal antibody for Lyme disease prophylaxis; TNX-1900 intranasal potentiated oxytocin for craniofacial pain conditions; TNX-1700 and TNX-4700 immuno-oncology programs; TNX-801 vaccine research; and TNX-1500 for prevention of kidney transplant rejection. Other company developments include scientific presentations, clinical and preclinical data, commercial access arrangements, operating results, capital-structure disclosures and governance matters.
Tonix Pharmaceuticals (Nasdaq: TNXP) has secured an exclusive license from Curia Global, Inc. for the development of three humanized murine monoclonal antibodies aimed at treating or preventing SARS-CoV-2 infections. This move comes as existing monoclonal antibody therapies struggle with new COVID-19 variants. CEO Seth Lederman emphasized the need for next-generation treatments, especially for immunocompromised individuals at higher risk of severe outcomes. Tonix aims to leverage its capabilities to expand its COVID-19 therapeutic pipeline.
Tonix Pharmaceuticals (Nasdaq: TNXP) announced a sponsored research agreement with Boston Children's Hospital to evaluate TNX-1500, an Fc-modified anti-CD40L monoclonal antibody, for preventing graft-versus-host disease (GvHD) after hematopoietic stem cell transplantation (HCT). The study, led by Dr. Leslie Kean, aims to assess TNX-1500's effectiveness in modifying GvHD progression in animal models, supporting future human trials. A Phase 1 study for TNX-1500 is expected to start in the first half of 2023, targeting improved treatment outcomes for hematologic malignancies.
Tonix Pharmaceuticals (Nasdaq: TNXP) presented data on TNX-801, a live horsepox virus vaccine, at the World Vaccine and Immunotherapy Congress. CEO Seth Lederman emphasized that TNX-801 could offer better protection against monkeypox and smallpox compared to modern vaccines. The company plans to initiate a Phase 1 clinical study in Kenya in H1 2023 and has reported positive data from non-human primates showing complete protection from monkeypox. TNX-801 is based on the 1976 horsepox strain, suggesting it has a close genetic link to Edward Jenner's original smallpox vaccine.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) presented data on its fully human anti-SARS-CoV-2 monoclonal antibody platform at the World Antiviral Congress 2022. Collaborating with Columbia University, the project aims to enhance understanding of immune responses to COVID-19 and develop targeted therapeutics. CEO Seth Lederman emphasized the necessity for second-generation monoclonal antibody treatments due to new variants and declining efficacy of existing ones. The company is exploring rapid development of novel therapeutics from patient samples, showcasing its capabilities in biologics manufacturing.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced its participation in the A.G.P. Biotech Conference, scheduled for November 30 - December 1, 2022. The conference will be virtual, allowing management to engage in investor meetings. Interested investors can arrange meetings via the conference coordinator. Tonix focuses on developing therapeutics for CNS disorders, rare diseases, immunology, and infectious diseases. Key products under development include TNX-102 SL for fibromyalgia and TNX-1300 for cocaine intoxication. Upcoming studies include Phase 2 trials for various treatments in 2023.
Tonix Pharmaceuticals (Nasdaq: TNXP) announced that CEO Seth Lederman will present at the World Vaccine and Immunotherapy Congress 2022 in San Diego from November 28 to December 1, 2022. The presentation, titled ‘Showcase 1: Early Development of Smallpox & Monkey Pox Vaccines,’ is scheduled for December 1 at 10:40 a.m. PT. Tonix focuses on developing therapeutics for various diseases, with key candidates in CNS disorders, rare diseases, and infectious diseases. Future studies for multiple product candidates are anticipated in 2023.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) presented data on oxytocin's effects on isolated human sensory neurons at Neuroscience 2022. This study indicates oxytocin's potential role in pain modulation, citing evidence that it may serve as a non-opioid analgesic. The company anticipates starting a Phase 2 study of intranasal oxytocin for chronic migraine by 2022's end. Prior findings showed oxytocin receptors on sensory neurons, with inflammation increasing receptor presence. Additionally, magnesium significantly enhances oxytocin's analgesic effects, supporting its therapeutic use.
Tonix Pharmaceuticals (Nasdaq: TNXP) announced a poster presentation at the Neuroscience 2022 conference, scheduled for November 12-16, 2022, in San Diego. The presentation, titled “In Vitro Impact of Oxytocin on Human Sensory Neurons”, will occur on November 14, 2022, from 1:00 p.m. to 2:00 p.m. PT. Notable authors include Dr. David C. Yeomans from Stanford University and Tonix's Dr. David Hsu. The company continues to develop therapeutics for various conditions, with ongoing studies for fibromyalgia and Long COVID, while maintaining a focus on CNS, rare diseases, and immunology.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) reported third-quarter financial results for 2022, revealing cash and equivalents of $140 million. The company is advancing its pipeline, with a Phase 3 study for TNX-102 SL in fibromyalgia underway, and a Phase 2 study for Long COVID expected to show interim data in Q2 2023. R&D expenses rose to $22.2 million, driven by increased clinical activities, leading to a net loss of $29 million, or $0.69 per share. Tonix's diverse pipeline targets CNS disorders, rare diseases, and infectious diseases, with several trials anticipated to start soon.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced that COO Jessica Morris will present at BioFuture on November 8, 2022, at 11:00 a.m. ET, at the Lotte New York Palace. During the event, she will host investor meetings. Interested investors can register for meetings via the BioFuture website. Tonix is focused on developing therapeutics for CNS, rare diseases, immunology, and infectious diseases, with key candidates in advanced stages, including TNX-102 SL for fibromyalgia and TNX-1300 for cocaine intoxication.